Compare Inovio Pharmaceuticals Inc (INO) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Union Pacific Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $91.32M), while Union Pacific Corporation trades at $297.17 (market cap $179.15B). The key difference: Union Pacific Corporation is far larger — about 1961.8× Inovio Pharmaceuticals Inc's market cap, and Union Pacific Corporation pays a 1.83% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | UNP | |
|---|---|---|
Market Cap | $91.32M | $179.15B |
Sector | Health | Industrials |
52-Week High | $2.87 | $301.75 |
52-Week Low | $1.05 | $214.91 |
Enterprise Value | $62.34M | $209.62B |
Dividend Yield | — | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.085, down 3.12% on the day, with a bearish technical signal and negative cash flow. The company reported minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Positive Phase 3 results for VGX-3100 in China and an upcoming FDA decision on INO-3107 in October 2026 are key catalysts, but shareholder litigation and high cash burn pose significant risks.
The outlook hinges on regulatory approval for INO-3107, with analyst consensus leaning buy (52.95%) but technicals and fundamentals indicating high risk. Success could drive substantial upside, but failure may exacerbate financial strain. Investors face a binary event-driven scenario with limited near-term revenue offset by promising clinical progress.
Union Pacific (UNP) trades at $299.46, down 0.76% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $311.07. The company reported strong Q1 2026 earnings of $2.93 per share, beating expectations, and maintains robust profitability with a 29.2% net income margin. Recent news highlights include the upcoming Q2 2026 earnings release on July 23, 2026, and ongoing merger discussions with Norfolk Southern.
The stock presents a favorable risk-reward profile with solid fundamentals and positive analyst sentiment, though risks include regulatory hurdles for the proposed merger and potential economic headwinds affecting freight demand. Institutional interest remains strong, with Allspring Global increasing its stake in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
